Anti-platelet drugs are necessary in treating patients with coronary artery disease,
ischemic stroke and peripheral arterial disease. However, despite the use of adequate
anti-platelet therapy, some patients will experience a recurrent atherothrombotic vascular
event. These patients are characterized as low- or non-responders to therapy. Individual
responsiveness to anti-platelet therapy as the use of clopidogrel and/or aspirin varies widely
among patients. Such an individual variability is mainly determined by environmental and
genetic factors. In this review, we focused on the underlying genetic mechanisms that might
influence response to anti-platelet drugs.
Keywords: Anti-platelet therapy, aspirin, ticagrelor, prasugrel, clopidogrel, GPIIb/IIIa inhibitors, acute coronary syndromes, cardiovascular
disease, gene polymorphisms, miRNAs.
Rights & PermissionsPrintExport